Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
2 hedge funds and large institutions have $112K invested in Albany Molecular Research Inc in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
Syntal Capital Partners
Midland,
Texas
|
+$112K |
Top Sellers
AMRI Hedge Fund Activity: Q3 2019 in Review
2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q3 2019, worth a combined $112K.
Buyers outnumbered sellers: 1 fund opened new AMRI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Syntal Capital Partners, opening a new position worth an estimated $112K.
- 2 institutional investors held Albany Molecular Research Inc (AMRI) as of Q3 2019, up from 1 in Q2 2019.
- Funds reported $112K of Albany Molecular Research Inc stock for Q3 2019.
- 1 fund opened new Albany Molecular Research Inc positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest Albany Molecular Research Inc buyer in Q3 2019 was Syntal Capital Partners, an estimated $112K added.
Based on aggregated 13F filings for Q3 2019.